Clinical trials: Beta Blockers
Myocardial Infarction
Cardiovascular Medication Use Before First Myocardial Infarction
Large randomised trials have shown that cardiovascular medications prescribed to patients at high cardiovascular risk are effective in reducing the incidence of cardiovascular events.
- Trial name
- NCT01692795
- Where
- United Kingdom
- Volunteers
- 17,000 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Cirrhosis, Compensated Cirrhosis
The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis
This pilot study to determine the feasibility of EUS-Portal Pressure Measurements to guide Beta-Blocker Therapy in patients with compensated cirrhosis .The study will be a prospective tandem controlled trial consisting of 30…
- Conditions
- Cirrhosis, Compensated Cirrhosis, Portal Hypertension
- Trial name
- NCT05357599
- Testing
- EUS
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Diabetes Mellitus, Type 2, Hypertension
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is…
- Trial name
- NCT00430040
- Testing
- Carvedilol Controlled Release (CR), lisinopril
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University at Buffalo
Acute on Chronic Liver Failure
Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices
Acute on chronic liver failure patients with HVPG (Hepatic Venous Pressure Gradient) ≥ 12 mmHg + No/small esophageal varices who present to the Department of Hepatology at Institute of Liver and Billiary Sciences, who meet the…
- Trial name
- NCT02583698
- Testing
- Carvedilol
- Where
- India
- Volunteers
- 136 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
TBI (Traumatic Brain Injury)
Propranolol for the Treatment of Traumatic Brain Injury
Traumatic brain injury (TBI) is a leading cause of global disease and directly affects over 1.5 million Canadians, with 165 000 TBIs occurring yearly in Canada.
- Trial name
- NCT06262061
- Testing
- Propranolol
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre
Acute Respiratory Distress Syndrome (ARDS)
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
Randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Respiratory Distress Syndrome (ARDS).
- Trial name
- MAIDEN (NCT05847517)
- Testing
- Metoprolol Injection, saline 0.9%
- Where
- 12 sites in Spain
- Volunteers
- 14 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Atrial Fibrillation
Safety Study of Tecadenoson to Treat Atrial Fibrillation
Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate.
- Trial name
- NCT00713401
- Testing
- Tecadenoson, Esmolol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers
Beta Adrenergic Antagonist for the Healing of Chronic DFU
One in four Veterans is affected by diabetes and will develop a diabetic foot ulcer. Diabetic ulcers are very challenging to manage and are the most common cause of leg amputation.
- Conditions
- Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
- Trial name
- BAART-DFU (NCT03282981)
- Testing
- Timolol, Non biologically active gel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- VA Office of Research and Development
Acute Coronary Syndrome
The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction
The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary…
- Trial name
- NCT04564365
- Testing
- beta-blocker
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Medical University
Hypertension
The Effects of Nifedipine and Metoprolol on Blood Pressure Variability in Northern Chinese
Hypertension is one of the most common cardiovascular diseases, which is a major risk factor for stroke and cardiovascular events.
- Trial name
- NCT02513927
- Testing
- metoprolol, Nifedipine
- Where
- Hungary
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Pulmonary Disease, Chronic Obstructive
Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that will enroll 1028 patients with at least moderately severe COPD over a three year period and follow them at regular intervals for one…
- Trial name
- NCT02587351
- Testing
- Metoprolol succinate
- Where
- 27 sites in United States
- Volunteers
- 532 people
- Sponsor
- University of Minnesota
Atrial Fibrillation, Diastolic Dysfunction
Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor
The goal of this study is to test the feasibility of guiding as-needed pharmacological rate control of atrial fibrillation (AF) by implantable cardiac monitors and to assess the impact of continuous beta-blocker therapy versus…
- Conditions
- Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT05745337
- Testing
- As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Vermont
Hypertension
Pharmacogenomic Evaluation of Antihypertensive Responses
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging.
- Trial name
- NCT00246519
- Testing
- Hydrochlorothiazide, Atenolol
- Where
- 3 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- University of Florida
Takotsubo Cardiomyopathy, Beta-blockers
Beta-Blockers in Takotsubo Syndrome Study
The Beta-blockers in Takotsubo syndrome (TTS) (β-Tako) trial, is an academic, pragmatic, prospective, multicenter randomized clinical trial, aiming to assess the efficacy of beta-blockers (BB) in TTS patients.
- Conditions
- Takotsubo Cardiomyopathy, Beta-blockers, Echocardiography, Left Ventricular Function
- Trial name
- β-Tako (NCT06509074)
- Testing
- Beta blocker
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Society of Cardiology
Septic Shock
POCUS-Guided Esmolol in Septic Shock: A Pilot RCT
The goal of this pilot clinical trial is to determine if conducting a larger study using point-of-care ultrasound (POCUS) to guide beta-blocker therapy in patients with septic shock is feasible.
- Trial name
- Epic-Beta (NCT07313605)
- Testing
- Esmolol
- Volunteers
- 100 people
- Sponsor
- John Basmaji
Hyperalgesia
Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids
This research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil).
- Trial name
- NCT01222091
- Testing
- Propranolol, Remifentanil
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Glaucoma
MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular…
- Trial name
- NCT00449956
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, Comparator: dorzolamide hydrochloride
- Volunteers
- 474 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatic Cirrhosis
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
Multicentric, observational and prospective study with two groups of treatment: Refractory ascites and non-refractory ascites. All patients should be prescribed beta-adrenergic blockers as primary or secondary profilaxis for…
- Trial name
- ALB-BET (NCT02163512)
- Where
- 2 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Adrenergic Beta-Antagonists, Stable Angina Pectoris
A Randomized, Two-arm, Open Label Study to evalUate the Effect of a Smart Phone-based Patient Support Tool On Patient AdheRence of Treatment in Stable Angina Patients Prescribed Beta-blockers in China (SUPPORT)
The present study aims to enhance the adherence of beta-blockers by Patient Support Tool through a smart phone application and a wristband, subsequently reduce the risk of angina attacks in patients with stable angina pectoris.
- Conditions
- Adrenergic Beta-Antagonists, Stable Angina Pectoris, Medication Adherence, Mobile Applications
- Trial name
- NCT03794713
- Testing
- Patient support tool
- Volunteers
- 432 people
- Sponsor
- Shenyang Northern Hospital
Chronic Obstructive Pulmonary Disease
Beta-blockers to Patients With Chronic Obstructive Pulmonary Disease
Background: In patients with chronic obstructive pulmonary disease (COPD) and concomitant cardiovascular conditions cardio-selective beta-blockers reduce mortality and can be used without significant negative effects on lung…
- Trial name
- NCT03566667
- Testing
- Metoprolol, Standard care
- Where
- Sweden
- Volunteers
- 1,713 people
- Sponsor
- Ole Frobert, MD, PhD